A national tumor board helps DIPG and DMG families find trials
Original title: The DIPG/DMG National Tumor Board: The power of advocacy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This board is running today, and families can ask for a review.
The short version
A free expert panel, started by parents, reviews DIPG and DMG cases and points families toward clinical trials.
What was studied. Doctors looked back at cases brought to the DIPG/DMG National Brain Tumor Board between November 2022 and December 2024. They counted who was referred, where they came from, and what the board advised.
What they found. The board reviewed 349 case presentations covering 279 patients. Referrals came from 93 institutions across 35 states. About 48% came from a treating doctor, 34% came from families themselves, and 18% came through My DIPG Navigator. Most patients, 83%, had a tumor biopsy. The board usually gave families six clinical trial options, and a second look at scans added new findings or advice in over half of cases.
What this means, and what it doesn't
What it could mean: A family with DIPG or DMG can have their case seen by a group of experts, even if they do not live near a large cancer center. Families can ask for a review themselves. The main help is finding trials and getting a second opinion on scans and test results.
What it doesn't mean: This is not a treatment, and it is not a cure. The board does not give drugs or care. It gives advice and trial options. This report only counted what the board did. It did not test whether patients lived longer or felt better. Being told about a trial does not mean a person will qualify for it or get a spot.
Source: PubMed, October 11, 2025 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.